Nature Communications 6, Article number: 795610.1038/ncomms8956 (2015); Published 08032015; Updated 02052016

After reanalysing the RNA sequencing data presented in Supplementary Data 3 of this Article, we have discovered that 341,056 of the 730,620 expression values were inadvertently paired with incorrect gene names. These incorrect values were used in [Figure 3c--e](#f3){ref-type="fig"} and Supplementary Tables 4,5,7 and 8 and led us to conclude that there are differences in the expression of DNA repair and apoptosis genes between CA125-negative and CA125-positive cells. We have now reanalysed the corrected data, and present a revised version of [Figure 3](#f3){ref-type="fig"} below. We find that, of the DNA repair and apoptosis genes reported in [Figure 3](#f3){ref-type="fig"}, none display a statistically significant difference in expression between CA125-negative and CA125-positive cells at the transcript level. However, at the protein level, cIAPs, the target proteins for Birinapant, are nevertheless expressed at substantially higher levels by CA125-negative cells, implying that the regulatory mechanisms of cIAP protein expression may be different from transcriptional regulation in CA125-negative cells. Therefore, the overall conclusion in regard to therapy, that birinapant strongly sensitizes CA125-negative cells to carboplatin-induced death due to their high cIAP protein expression, remains unaffected by the error in RNA-sequencing data analysis. Corrected versions of Supplementary Data 3 and Supplementary Tables 4,5,7 and 8 are available from the HTML version of this Corrigendum.
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